Treatment of collecting duct carcinoma: current status and future perspectives

Anticancer Res. 2014 Feb;34(2):1027-30.


Background: Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated the activity of targeted therapies in metastatic CDC.

Patients and methods: We evaluated a cohort of 384 consecutive patients with metastatic renal cell carcinoma (mRCC). The characteristics of patients with CDC were compared against those of the remaining cohort. All patients with CDC were treated with targeted therapies.

Results: Thirteen patients with advanced CDC were referred to our Center (incidence: 3.4% of all mRCC). Median age was 57 and 62 years in the CDC and non-CDC groups, respectively. The overall disease control in the CDC population was 23%, and median overall survival was 4 (95% confidence interval(CI)=2.4-5.6) months. Three patients obtained a satisfying response (disease control lasting 6-33 months).

Conclusion: CDC has a poor prognosis compared to non-CDC renal cell carcinoma. Treatment for CDC represents a future challenge and targeted therapies may play a role in selected cases.

Keywords: Bellini disease; collecting ducts carcinoma; renal carcinoma; targeted therapy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / blood supply*
  • Carcinoma, Renal Cell / drug therapy*
  • Cohort Studies
  • Humans
  • Indazoles
  • Kidney Neoplasms / blood supply*
  • Kidney Neoplasms / drug therapy*
  • Middle Aged
  • Neovascularization, Pathologic / drug therapy
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use
  • Pyrimidines / therapeutic use
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Sorafenib
  • Sulfonamides / therapeutic use


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indazoles
  • Phenylurea Compounds
  • Pyrimidines
  • Sulfonamides
  • Niacinamide
  • temsirolimus
  • pazopanib
  • Sorafenib
  • Sirolimus